Search

Displaying results 3931 - 3940 of 4246 in total
  1. Drug

    DG041

    go.drugbank.com/drugs/DB05027
    Experimental

    DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications. DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of th...

  2. Drug

    Terevalefim

    go.drugbank.com/drugs/DB16397
    Investigational

    Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).

  3. Drug

    Teprenone

    go.drugbank.com/drugs/DB15955
    Investigational

  4. Drug

    Dental Mesenchymal Pulp Stem Cells

    go.drugbank.com/drugs/DB15737
    Investigational

    These cells have innate neurogenic potential as their origins are traced to the embryonic neural crest; there is potential for these cells to create neurons and glial cells. … They are harvested through surgical extraction of wisdom teeth from adults; this procedure is favoured as it is non-invasive, easily accessible, and allows for an alternate use of teeth that are usually

  5. Drug

    Atl146e

    go.drugbank.com/drugs/DB05191
    Investigational

    ATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.

  6. Drug

    Mosedipimod

    go.drugbank.com/drugs/DB12592
    Investigational

    Mosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.

  7. Drug

    CYP-001

    go.drugbank.com/drugs/DB15739
    Investigational

    CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are...

  8. Drug

    MKC1106-PP

    go.drugbank.com/drugs/DB06030
    Experimental

    MKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM. The plasmid portion is a recombinant plasmid expressing segments of the 2 target antigens, PRAME and PSMA. MKC1106-PP...

  9. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders.

  10. Drug

    NLX-P101

    go.drugbank.com/drugs/DB05924
    Experimental

    NLX-P101 is being evaluated as a therapeutic drug when injected into this deep brain structure that is known to function abnormally in Parkinson’s patients.